US Stock MarketDetailed Quotes

CDXC ChromaDex

Watchlist
  • 7.830
  • -0.050-0.63%
Trading Mar 11 10:23 ET
608.79MMarket Cap71.18P/E (TTM)

About ChromaDex Company

Chromadex Corp. is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. It is pioneering research on nicotinamide adenine dinucleotide (NAD+). The company’s patent portfolio includes Nicotinamide Riboside (NR) and other NAD+ precursors, which are commercialized as the flagship ingredient Niagen. It operates through the following segments: Consumer Products, Ingredients, and Analytical Reference Standards and Services. The Consumer Products segment provides finished dietary supplement products that contain the firm’s proprietary ingredients directly to consumers as well as to distributors. The Ingredients segment supplies ingredients as raw materials to the manufacturers of consumer products. The Analytical Reference Standards and Services segment includes supply of phytochemical reference standards and other research and development services. The company was founded by Mark S. Germain and Frank L. Jaksch, Jr. in 1999 and is headquartered in Los Angeles, CA.

Company Profile

SymbolCDXC
Company NameChromaDex
Listing DateApr 25, 2016
Founded1999
CEOMr. Robert N. Fried
MarketNASDAQ
Employees104
Fiscal Year Ends12-31
Address10900 Wilshire Boulevard,Suite 600
CityLos Angeles
ProvinceCalifornia
CountryUnited States of America
Zip Code90024
Phone1-310-388-6706

Company Executives

  • Name
  • Position
  • Salary
  • Robert N. Fried
  • Chief Executive Officer and Director
  • 1.16M
  • Ozan Pamir
  • Chief Financial Officer and Principal Accounting Officer
  • --
  • Frank L. Jaksch, Jr
  • Chairman of the Board
  • 92.31K
  • Kristin Patrick
  • Independent Director
  • 82.31K
  • Gary Ng
  • Independent Director
  • 69.81K
  • Wendy Yu
  • Independent Director
  • 67.31K
  • Hamed Shahbazi
  • Independent Director
  • 67.31K
  • Steven D. Rubin
  • Lead Independent Director
  • 117.31K
  • Ann Cohen
  • Independent Director
  • 89.81K
  • Jeong James Lee
  • Controller
  • --
Trending Stocks
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries

Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only. This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only. This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.